Fate Therapeutics Inc (FATE)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $155.74M
Last updated: Nov 17, 2026 at 11:06 AM ET
Performance (10Y)
Upcoming Estimates
Key Metrics
Technical Indicators Dashboard
As of Nov 16, 2026, the price is 46.4% below its 50-day moving average, and the 50-day average is above the 200-day average. The 14-day RSI is 21.1, below 30, the oversold line.
Moving Averages
MACD
ADX
Aroon & PSAR
Bollinger Bands
RSI (14-Day)
Momentum Oscillators
Volatility Measures
Volume Flow
Volume Metrics
Pivot Points
Advanced Oscillators
Financial Performance
Related GNG Research
No research available
Be the first to write about FATE
News
FATE Valuation
FATE Profitability: Margins, ROIC and FCF
Fate Therapeutics (FATE) has an operating margin of -2737.0% and a net margin of 0.0%. It posts -51.3% ROIC and a -2252.1% FCF margin.
- Operating margin
- -2737.0%
- Net margin
- 0.0%
- ROIC
- -51.3%
- ROE
- -67.8%
- FCF margin
- -2252.1%
Fate Therapeutics Competitors
The companies most similar to Fate Therapeutics (FATE) include Lineage Cell Therapeutics, Protara Therapeutics and Invivyd.
Sector: Healthcare
Companies most similar to Fate TherapeuticsFATE Analyst Ratings
Fate Therapeutics (FATE) has a Buy consensus from 11 analysts: 5 Buy or Strong Buy, 6 Hold and 0 Sell or Strong Sell.
- Consensus
- Buy
- Analysts
- 11
- Strong Buy
- 1
- Buy
- 4
- Hold
- 6
- Sell
- 0
- Strong Sell
- 0
FATE Bull Case vs Bear Case
Bull case
- FATE beat EPS estimates in 75.0% of its last 8 reported quarters.
FATE Earnings: Beat Rate and Next Report
Fate Therapeutics (FATE) beat the EPS estimate in 6 of the last 8 quarters (75.0%). Its next report is expected on Feb 24, 2027.
- Beat rate
- 6 of 8 quarters (75.0%)
- Average surprise
- 6.9%
- EPS estimate (fiscal period ending Dec 31, 2026)
- -$0.25
FATE Earnings Date
FATE reports Feb 24, 2027. The date is estimated.
FATE ETF Holders
GNG tracks 5 ETFs that hold FATE. The largest weights:
- Vanguard Total Stock Market Index Fund Admiral Shares (VTSAX), <0.01% of the fund
- iShares Russell 2000 ETF (IWM), <0.01% of the fund
- Vanguard Health Care Index Fund ETF Shares (VHT), <0.01% of the fund
- Vanguard Morningstar Total Stock Market ETF (VTI), <0.01% of the fund
- Vanguard Russell 2000 Index Fund ETF Shares (VTWO), <0.01% of the fund
Updated Nov 5, 2026. Built from end-of-day prices, company filings and consensus analyst estimates. Methodology
Frequently Asked Questions About FATE
When does FATE report earnings?
Fate Therapeutics Inc (FATE) is expected to report earnings on Feb 24, 2027.
Does FATE pay dividends?
Fate Therapeutics Inc (FATE) does not currently pay a regular dividend.
What is FATE's market cap?
Fate Therapeutics Inc (FATE) has a market capitalization of $155.74M with a current stock price of $1.14.
FATE pages: Overview, Earnings, Forecast, Financials, Competitors
Get full access to GNG Research
Create a free account to access portfolio tracking, advanced tools, and more.